View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 5, 2016updated 13 Jul 2022 10:13am

DBV Technologies begins patient enrolment in Phase I trial of Viaskin rPT to treat whooping cough

French clinical-stage specialty biopharmaceutical company DBV Technologies has begun enrolment for its proof of concept Phase I clinical trial of Viaskin rPT to treat Bordetella pertussis (whooping cough).

French clinical-stage specialty biopharmaceutical company DBV Technologies has begun enrolment for its proof of concept Phase I clinical trial of Viaskin rPT to treat Bordetella pertussis (whooping cough).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Bionet’s genetically detoxified pertussis toxin (rPT) is an optimised pertussis antigen intended to be delivered epicutaneously through DBV’s adjuvant-free patch technology, Viaskin.

Pertussis is an acute respiratory infection caused by small Gram-negative, aerobic bacteria known as bordetella pertussis.

It triggers symptoms such as severe, spasmodic coughing episodes during the paroxysmal phase.

"This valuable collaboration with HUG and BioNet has the potential to be a breakthrough in vaccinations."

The Phase I proof-of-concept study is conducted in association with the Clinical Research Centre of Geneva University Hospitals (HUG), under the supervision of Professor Claire-Anne Siegrist and BioNet-Asia.

The dose-escalation, randomised, double-blind, placebo-controlled study intends to test the safety and immunogenicity of BioNet’s rPT through DBV’s Viaskin patches in 60 young healthy adults aged between 18-40 who have been vaccinated during childhood against pertussis.

The study will be divided into two cohorts with 30 patients each.

The first cohort will be treated with two dosages of rPT or placebo with the Viaskin patches applied for 48 hours with an interval of two weeks between each application.

After four weeks of the second Viaskin application, the subjects will receive a single dose of Boostrix dTpa vaccine to ensure activation of immunity against diphtheria, tetanus and the three pertussis antigens.

The secondary endpoint of the cohort is the evaluation of immune and cellular responses resulted by rPT.

The determination of the safety and tolerability of the first dose of Viaskin rPT 25 will pave the way for the initiation of treatment in the second cohort, which will treat the patients with two dosages of Viaskin rPT.

DBV Technologies chairman and CEO Dr Pierre-Henri Benhamou said: "Utilising the skin’s immune properties for vaccination is a paradigm shift in this field.

“Professor Siegrist and her team recently published a paper with pre-clinical data, showing that a single application of Viaskin rPT on intact skin was capable of reactivating whooping cough immunity without the use of adjuvants.

“This valuable collaboration with HUG and BioNet has the potential to be a breakthrough in vaccinations: if Professor Siegrist and her team can replicate the in vivo results in humans, Viaskin rPT could be the first non-invasive and self-administrable vaccine to be developed for boosting pertussis immunity."

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena